191 related articles for article (PubMed ID: 37142595)
1. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
Källberg J; Harrison A; March V; Bērziņa S; Nemazanyy I; Kepp O; Kroemer G; Mouillet-Richard S; Laurent-Puig P; Taly V; Xiao W
Cell Death Dis; 2023 May; 14(5):306. PubMed ID: 37142595
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.
Chen RM; Chiou YS; Chong QY; Poh HM; Tan TZ; Zhang MY; Ma L; Zhu T; Pandey V; Basappa ; Kumar AP; Lobie PE
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835445
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
[TBL] [Abstract][Full Text] [Related]
4. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.
Deng J; Tian AL; Pan H; Sauvat A; Leduc M; Liu P; Zhao L; Zhang S; Chen H; Taly V; Laurent-Puig P; Senovilla L; Li Y; Kroemer G; Kepp O
Cell Death Dis; 2021 Oct; 12(11):978. PubMed ID: 34675191
[TBL] [Abstract][Full Text] [Related]
5. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
7. A Gene Signature Derived from the Loss of CDKN1A (p21) Is Associated with CMS4 Colorectal Cancer.
Bueno-Fortes S; Muenzner JK; Berral-Gonzalez A; Hampel C; Lindner P; Berninger A; Huebner K; Kunze P; Bäuerle T; Erlenbach-Wuensch K; Sánchez-Santos JM; Hartmann A; De Las Rivas J; Schneider-Stock R
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008299
[TBL] [Abstract][Full Text] [Related]
8. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
9. miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.
Liu H; Yin Y; Hu Y; Feng Y; Bian Z; Yao S; Li M; You Q; Huang Z
Pathol Res Pract; 2016 Jul; 212(7):643-9. PubMed ID: 27173050
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
[TBL] [Abstract][Full Text] [Related]
11. A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
Robles J; Pintado-Berninches L; Boukich I; Escudero B; de Los Rios V; Bartolomé RA; Jaén M; Martín-Regalado Á; Fernandez-Aceñero MJ; Imbaud JI; Casal JI
J Pathol Clin Res; 2022 Nov; 8(6):495-508. PubMed ID: 36134447
[TBL] [Abstract][Full Text] [Related]
12. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
13. Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
Kim HG; Kim CW; Lee DH; Lee JS; Oh ET; Park HJ
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491980
[TBL] [Abstract][Full Text] [Related]
14. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
[TBL] [Abstract][Full Text] [Related]
15. SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer.
Qu YL; Liu XL; Zhao SY; Zhai XF
Pathol Res Pract; 2022 Jun; 234():153895. PubMed ID: 35462225
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
17. Differential CMS-Related Expression of Cell Surface Carbonic Anhydrases IX and XII in Colorectal Cancer Models-Implications for Therapy.
Rotermund A; Brandt S; Staege MS; Luetzkendorf J; Mueller LP; Mueller T
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982873
[TBL] [Abstract][Full Text] [Related]
18. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
19. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
Xu F; Ye ML; Zhang YP; Li WJ; Li MT; Wang HZ; Qiu X; Xu Y; Yin JW; Hu Q; Wei WH; Chang Y; Liu L; Zhao Q
Cancer Sci; 2020 May; 111(5):1528-1541. PubMed ID: 32073706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
